Immune Design Corp (NASDAQ:IMDZ) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.19.

Several research analysts have recently commented on IMDZ shares. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Immune Design in a report on Monday, December 3rd. Zacks Investment Research raised Immune Design from a “sell” rating to a “hold” rating in a report on Wednesday, October 3rd. Leerink Swann downgraded Immune Design from an “outperform” rating to a “market perform” rating in a report on Friday, October 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $11.00 target price on shares of Immune Design in a report on Friday, October 12th.

In other news, major shareholder Bvf Partners L. P/Il sold 902,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $1.83, for a total value of $1,650,660.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 18.10% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of IMDZ. Marshall Wace LLP bought a new position in Immune Design in the 3rd quarter worth approximately $36,000. Nexthera Capital LP bought a new position in Immune Design in the 3rd quarter worth approximately $146,000. Tiverton Asset Management LLC bought a new position in Immune Design in the 2nd quarter worth approximately $176,000. Bank of America Corp DE raised its position in Immune Design by 231.9% in the 2nd quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 32,669 shares during the last quarter. Finally, DRW Securities LLC raised its position in Immune Design by 59.2% in the 2nd quarter. DRW Securities LLC now owns 58,900 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 21,900 shares during the last quarter. Hedge funds and other institutional investors own 46.27% of the company’s stock.

NASDAQ IMDZ opened at $2.01 on Friday. The company has a market cap of $84.77 million, a price-to-earnings ratio of -1.15 and a beta of 2.56. Immune Design has a 1-year low of $1.25 and a 1-year high of $5.05.

Immune Design (NASDAQ:IMDZ) last announced its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. The business had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.75 million. Immune Design had a negative return on equity of 43.44% and a negative net margin of 2,409.84%. Equities research analysts predict that Immune Design will post -1.14 EPS for the current fiscal year.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Recommended Story: Marijuana Stocks

Analyst Recommendations for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.